( May 7, 2026, 00:31 GMT | Official Statement) -- MLex Summary: The proposed acquisition by Medtronic, via its indirect wholly owned subsidiary Project Saint Merger Sub, of US-based Scientia Vascular, will be reviewed by Australia’s antitrust watchdog. In a statement on Wednesday, the Australian Competition & Consumer Commission said Medtronic and Scientia supply neurovascular guidewires in Australia. The regulator said that Medtronic, a global healthcare technology company listed on the New York Stock Exchange, supplies its Mirage .008-inch guidewire in Australia, while Scientia supplies guidewires under its “Aristotle” brand through a third-party distributor, LifeHealthcare. The watchdog is seeking feedback on the deal until May 13.Statement follows. Questionnaire is attached....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.